Patents Examined by Sergio Coffa
  • Patent number: 12378292
    Abstract: Certain embodiments of the present invention relate to regulation of the innate immune system and complement activation. In particular, but not exclusively certain embodiments relate to a complement regulator protein and pharmaceutical compositions thereof for use in the treatment of diseases associated with or mediated by the alternative complement pathway and methods of treating such diseases and other subject matter.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: August 5, 2025
    Assignee: University of Newcastle Upon Tyne
    Inventors: Kevin Marchbank, Yi Yang
  • Patent number: 12370245
    Abstract: The invention features immunogenic compositions containing anaplastic lymphoma kinase (ALK) polypeptides and methods of use thereof. The immunogenic compositions and methods of the invention may be used to treat a disease associated with ALK in a subject, such as cancer (e.g., a solid tumor cancer or an ALK+ cancer).
    Type: Grant
    Filed: February 28, 2023
    Date of Patent: July 29, 2025
    Assignee: Elicio Therapeutics, Inc.
    Inventors: Adrienne Li, Jackson Eby, Peter C. Demuth
  • Patent number: 12371463
    Abstract: Provided in this disclosure are methods of treating a bacterial infection comprising administering a formulation comprising an antimicrobial peptide described herein when administered to a subject. Further provided herein are methods of treating a bacterial infection wherein the bacterial infection comprises a bacterium with a mutation in a gene resulting in antibiotic resistance.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: July 29, 2025
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Vaughn Cooper, Alfonso Santos López
  • Patent number: 12351652
    Abstract: [Problem to be solved] To provide a compound having markedly higher antiviral activity than iHA 100, an intermediate for producing the compound, and a medical drug, or the like, containing the high-activity compound above. [Solution] The invention relates to a hemagglutinin-binding peptide, a pharmaceutically acceptable salts, or a solvate thereof, the hemagglutinin-binding peptide being: (1) a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2: Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys (SEQ ID NO: 1), Trp-Thr-MeGly-Asp-MePhe-MePhe-Ala-MeAla-His-Tyr-Thr-Val-hydPro-Ala-Cys-Lys (SEQ ID NO: 2), or the like.
    Type: Grant
    Filed: February 17, 2020
    Date of Patent: July 8, 2025
    Assignee: PeptiDream Inc.
    Inventors: Keiichi Masuya, Masaki Ohuchi
  • Patent number: 12351653
    Abstract: Provided herein are novel cyclic peptides, their synthetic process, compositions, properties including stability and pharmacokinetic profiles, and applications for treating solid tumor cancers.
    Type: Grant
    Filed: January 15, 2025
    Date of Patent: July 8, 2025
    Inventors: Harri Jarvelainen, Erkki Ruoslahti
  • Patent number: 12331073
    Abstract: The invention provides a method for preparing a biologically active complex, said method comprising dissolving a mixture of a polypeptide element, such as alphalactalbumin or fragments thereof, in powder form and oleic acid or a pharmaceutically acceptable salt thereof also in solid form, in an aqueous solvent comprising a mixture of at least two and preferably three salts, wherein the method is carried out at moderate temperatures. The preparation does not require extensive heating and so is simple and efficient to carry out.
    Type: Grant
    Filed: January 12, 2021
    Date of Patent: June 17, 2025
    Assignee: HAMLET PHARMA AB
    Inventors: Aftab Nadeem, Catharina Svanborg, Chin Shing Ho
  • Patent number: 12295988
    Abstract: The present invention relates to semaglutide for use in weight management.
    Type: Grant
    Filed: August 30, 2024
    Date of Patent: May 13, 2025
    Assignee: Novo Nordisk A/S
    Inventors: Lars Holm Damgaard, Soeren Oestergaard Hardt-Lindberg, Thomas Hansen
  • Patent number: 12286460
    Abstract: The invention relates to an isolated polypeptide encoded by Sghrt and related uses. In addition, methods of assessing a heart function, treating impaired heart function by inhibiting Sghrt, identifying a potential drug for treating impaired heart function, and dedifferentiating and/or proliferating a heart cell by inhibiting Sghrt are claimed.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: April 29, 2025
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Roger Sik Yin Foo, Vinh Dang Do
  • Patent number: 12281182
    Abstract: The present disclosure relates to solid state forms of Voclosporin and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 23, 2023
    Date of Patent: April 22, 2025
    Assignee: ASSIA CHEMICAL INDUSTRIES LTD.
    Inventors: Pavel Kolesa, Ladislav Cvak, Alexandr Jegorov, Katerina Ondruszova
  • Patent number: 12268729
    Abstract: The present invention provides an agent for the treatment or prophylaxis of a neurodegenerative disease, containing an apoptosis inhibitor of macrophage (AIM), an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: April 8, 2025
    Inventor: Toru Miyazaki
  • Patent number: 12264352
    Abstract: A method for enhancing extracellular vesicle production is described. A peptide that induces polymer formation is incubated with a cell culture which results in enhanced EV production. The peptide penetrates the cells and subsequently polymerizes upon exposure to enzymes (e.g. phosphatase) within the cell. The cells that contain the newly formed polymers have an increased production of EVs. These EVs can be harvested using centrifugation techniques.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: April 1, 2025
    Assignees: Research Foundation of the City University of New York, Japanese Foundation for Cancer Research
    Inventors: Hiroshi Matsui, Kiyotaka Shiba, Min A. Kang
  • Patent number: 12257309
    Abstract: Glucose-responsive zwitterionic polymer-insulin-saccharide compositions are provided according to aspects of the present disclosure which include a zwitterionic polymer, an insulin moiety, a saccharide moiety, and a saccharide binding molecule. Methods of use of glucose-responsive zwitterionic polymer-insulin-saccharide compositions according to aspects of the present disclosure include administration to human patients to alleviate conditions, such as diabetes, which are responsive to administration of insulin.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: March 25, 2025
    Assignee: Wayne State University
    Inventor: Zhiqiang Cao
  • Patent number: 12258424
    Abstract: Polypeptides and compositions having the polypeptides. Methods for treating cancer utilizing polypeptides and compositions having the polypeptides. The polypeptides can bind to human PD-L1 protein. The polypeptides can block the PD-1/PD-L1 interaction.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: March 25, 2025
    Inventors: Kun Cheng, Hao Liu, John Fetse, Umar-Farouk Mamani
  • Patent number: 12252556
    Abstract: Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 18, 2025
    Assignee: BACAINN BIOTHERAPEUTICS, LTD.
    Inventors: Chris Murphy, Ronald Farquhar, Roland E. Dolle
  • Patent number: 12247087
    Abstract: The present application provides a biological active peptide from seawater pearl, the sequence of which is Ile-Pro-Ser-Thr-Thr-Pro-Phe-Pro-Ser-Thr-Thr-Val-Ala-Thr-Thr-Thr-Met, and the name of which is SCOL polypeptide. The biological active peptide can improve an ACE2 enzyme activity to 3.76 times, and can be applied in preparation of a drug improving an ACE2 activity, treating hypertension, anti-heart failure, anti-tissue fibrosis, anti-inflammation, and type 2 diabetes mellitus and the complication thereof, and relieving neuropathic pain. The biological active peptide can be specifically bound to the ACE2, effectively inhibits the 65% binding between novel coronavirus S protein and the ACE2, can be applied in preparation of an anti-coronavirus infection drug as an inhibitor, and specifically applied in preparation of anti-novel coronavirus drug.
    Type: Grant
    Filed: January 18, 2024
    Date of Patent: March 11, 2025
    Assignees: ZHEJIANG QINGRONG BIOTECHNOLOGY DEVELOPMENT CO., LTD, YANGTZE DELTA REGION INSTITUTE OF TSINGHUA UNIVERSITY, ZHEJIANG
    Inventors: Xiaojun Liu, Rongqing Zhang, Jing Zhang, Zehui Yin, Liping Yao, Zhen Zhang
  • Patent number: 12240890
    Abstract: Provided herein are compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism. In particular, provided herein are compositions comprising modified peptide YY (PYY) peptides and therapeutic and/or prophylactic methods of use thereof.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: March 4, 2025
    Assignee: The University of Chicago
    Inventors: Eugene B. Chang, Joseph F. Pierre, Katharine A. Harris
  • Patent number: 12239633
    Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
    Type: Grant
    Filed: August 1, 2023
    Date of Patent: March 4, 2025
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Sadasivan Vidyasagar, Paul Okunieff, Lurong Zhang
  • Patent number: 12240921
    Abstract: SorCS2 related lipidated cyclic peptides, cyclic peptides, lipidated linear peptides, linear peptides which may be of use in medicine, and related aspects.
    Type: Grant
    Filed: May 10, 2024
    Date of Patent: March 4, 2025
    Assignee: Teitur Trophics ApS
    Inventors: Anders Dalby, Simon Mølgaard Jensen, Mathias Kaas Ollendorff, Kristian Strømgaard, Keld Fosgerau
  • Patent number: 12234267
    Abstract: The invention provides compositions and kits including at least one nucleic acid or polypeptide molecule encoding for a mutant CoChop protein. Methods of the invention include administering a composition comprising a mutant CoChop to a subject to preserve, improve, or restore phototransduction. Preferably, the compositions and methods of the invention are provided to a subject having impaired vision, thereby restoring vision to normal levels.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: February 25, 2025
    Assignee: Wayne State University
    Inventors: Zhuo-Hua Pan, Tushar Ganjawala, Qi Lu, Gary Abrams
  • Patent number: 12214009
    Abstract: Compositions and methods for improving bruising, stimulating elastin and/or collagen production, stimulating intrinsic hyaluronic acid production, stimulating adipogenesis, reducing inflammation, or combinations thereof are provided herein. Compositions and methods described herein may be used following a cosmetic procedure.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: February 4, 2025
    Assignee: Alastin Skincare, Inc.
    Inventors: Alan David Widgerow, John A. Garruto